Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2010; 16(41): 5233-5240
Published online Nov 7, 2010. doi: 10.3748/wjg.v16.i41.5233
Table 1 Clinical characteristics of patients with inflammatory bowel diseases
CD (n = 810)UC (n = 428)
Male/female (n)434/376202/226
Age (yr)37.1 ± 12.643.7 ± 15.0
Age at presentation (yr)126.5 ± 10.631.3 ± 13.4
Duration (yr)110.7 ± 8.412.6 ± 9.9
Familial IBD111.8%7.6%
Location in CD1
L128.2%
L218.9%-
L351.2%
L4 only1.7%
All L47.9%
Maximum extent in UC1
Proctitis-7.8%
Left-sided52.3%
Extensive39.9%
Behavior in CD1
B134.9%
B234.5%-
B330.7%
Perianal disease141.2%-
Frequent relapse in CD/chronic continuous in UC139.9%27.6%
Arthritis138.6%27.1%
Cutaneous17.8%5.9%
Occular17.7%3.8%
PSC12.4%3.8%
Steroid use/refractory181.1%/11.6%66.2%/12.3%
Azathioprine use168.3%29.3%
Anti-TNF use133.2%10.4%
Surgery in CD/colectomy in UC150.9%10.0%
Smoking habits2
No55.1%71.6%
Yes31.3%12.4%
Previous13.6%16.0%
1Clinical phenotype available in 789 Crohn's disease (CD) and 422 ulcerative colitis (UC) patients;
2Available in 691 CD and 388 UC patients. L1: Ileal; L2: Colon; L3: Ileocolonic; L4: Upper gastrointestinal; B1: Inflammatory; B2: Stenosing; B3: Penetrating. IBD: Inflammatory bowel disease; TNF: Tumor necrosis factor.
Table 2 Association between NKX2-3, IRGM and ECM1 polymorphisms and disease susceptibility in patients with inflammatory bowel disease
WT (%)HET (%)HOM (%)P valueCarrier (%)P valueOR (95%CI)MAFP valueOR (95%CI)
IRGM rs13361189
All CD (n = 808)636 (78.7)156 (19.3)16 (2.0)0.0601172 (21.3)0.0601-188 (11.6)0.029.36 (1.03-1.79)
Hungarian CD (n = 456)355 (77.9)89 (19.5)12 (2.6)NS12101 (22.1)NS12-113 (12.4)NS12-
Czech CD (n = 352)281 (79.8)67 (19.0)4 (1.2)NS1271 (20.2)NS12-75 (10.7)NS12-
All UC (n = 428)351 (82.0)76 (17.8)1 (0.2)NS1277 (18.0)NS12-78 (9.1)NS12-
Hungarian UC (n = 274)221 (80.7)52 (19.0)1 (0.3)NS1253 (19.3)NS12-54 (9.9)NS12-
Czech UC (n = 154)130 (84.4)24 (15.6)0NS1224 (15.6)NS12-24 (7.8)NS12-
All controls (n = 460)382 (83.0)75 (16.3)3 (0.7)-78 (17.0)--81 (8.8)--
Hungarian controls (n = 265)217 (81.9)46 (17.4)2 (0.7)-48 (18.1)--50 (9.4)--
Czech controls (n = 195)165 (84.6)29 (14.9)1 (0.5)-30 (15.4)--31 (7.9)--
NKX2 rs 10883365
All CD (n = 810)208 (25.7)389 (48.1)213 (26.2)0.0101602 (74.3)NS12-815 (50.3)0.0091.24 (1.06-1.48)
Hungarian CD (n = 457)115 (25.2)220 (48.1)122 (26.7)NS12342 (74.8)NS12-464 (50.8)NS12-
Czech CD (n = 353)93 (26.3)169 (47.9)91 (25.8)0.0701260 (73.7)NS1-351 (49.7)0.03011.31 (1.03-1.68)
All UC (n = 427)90 (21.1)226 (52.9)111 (26.0)0.0041337 (78.9)0.00611.52 (1.13-2.08)448 (52.5)0.0011.36 (1.13-1.63)
Hungarian UC (n = 274)56 (20.4)152 (55.5)66 (24.1)NS12218 (79.6)0.0701284 (51.8)0.060
Czech UC (n = 153)34 (22.2)74 (48.4)45 (29.4)0.0171119 (77.8)0.04611.63 (1.01-2.65)164 (53.6)0.00511.53 (1.14-2.07)
All controls (n = 469)136 (29.0)245 (52.2)88 (18.8)-333 (71.0)--421 (44.9)--
Hungarian controls (n = 271)73 (26.9)145 (53.5)53 (19.6)-198 (73.1)--251 (46.3)--
Czech controls (n = 198)63 (31.8)100 (50.5)35 (17.7)-135 (68.2)--170 (42.9)--
ECM1 rs13294
All CD (n = 807)139 (17.2)392 (48.6)276 (34.2)NS12688 (82.8)NS12-944 (58.5)NS12-
Hungarian CD (n = 455)89 (19.6)228 (50.1)138 (30.3)NS12366 (80.4)NS12-504 (55.4)NS12-
Czech CD (n = 352)50 (14.2)164 (46.6)138 (39.2)NS12302 (85.8)NS12-440 (62.5)NS12-
All UC (n = 428)77 (18.0)225 (52.6)126 (29.4)NS12351 (82.0)NS12-477 (55.7)NS12-
Hungarian UC (n = 275)44 (16.0)156 (56.1)75 (27.3)NS12231 (84.0)NS12-306 (55.6)NS12-
Czech UC (n = 153)33 (21.6)69 (45.1)51 (33.3)NS12120 (78.4)NS12-171 (55.9)NS12-
All controls (n = 463)90 (19.4)222 (47.9)151 (32.6)-373 (80.6)--524 (56.6)--
Hungarian controls (n = 265)56 (21.1)124 (46.8)85 (32.1)-209 (78.9)--294 (55.5)--
Czech controls (n = 198)34 (17.2)98 (49.5)66 (33.3)-164 (82.8)--230 (58.1)--
1P value vs controls;
2P value Crohn's disease (CD) vs ulcerative colitis (UC). WT: Wild-type; HET: Heterozygous carrier; HOM: Homozygous carrier; MAF: Minor allele frequency; NS: Not significant.